SAN FRANCISCO (Thomson Finacial) - Novo-Nordisk AS said a head-to-head study demonstrated that Levemir (insulin detemir) can be used once-daily and had a comparable blood glucose response to insulin glargine, the active ingredient in Sanofi-Aventis SA's Lantus over a 24-hour period in patients with type 2 diabetes.
The findings were announced Monday at the American Diabetes Association (ADA) meeting.
A retrospective study using recent data from a large US health plan database showed that in addition to providing similar blood glucose response as glargine, Levemir had no significant difference against glargine in daily average consumption and diabetes related pharmacy costs.
Novo Nordisk also announced the first and only full scale study of once-daily Levemir versus a single daily dose of glargine to generate the first robust comparative data set of the two treatments.
Mads Krogsgaard Thomsen, chief science officer, said:. 'In clinical trials with patients with type 2 diabetes, once-daily Levemir has repeatedly shown 24-hour glycemic control, improved HbA1c control and a low incidence of hypos, with the addition of a weight benefit. For people with diabetes, once-daily Levemir may offer an attractive package.' tf.TFN-Europe_newsdesk@thomson.com lam/lam COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
